Nirav Shah, DO
Pulmonary Disease · Freehold, NJNPI 1720299340
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,225 of the $12,723 with a category attached, or 72.5%. Boehringer Ingelheim accounts for 76.5% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $9,345 and has fallen 95.6% since, to $408 in 2025.
Across 170 payments — averaging $74.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- AstraZeneca$583
- GSK$377
- Bristol Myers Squibb$299
- Pulmonx Corporation$284
- Boston Scientific$154
- plus $1K from 27 others
Across 37 payments — averaging $4022.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$149K
What the payments were for
- Speaking & faculty fees$9,22573%
- Travel & lodging$2992%
- Food & beverage$3,17625%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 30 | $9,729 |
| AstraZeneca | 32 | $583 |
| GSK | 27 | $377 |
| Bristol Myers Squibb | 1 | $299 |
| Pulmonx Corporation | 2 | $284 |
| Boston Scientific | 1 | $154 |
| Philips North America LLC | 9 | $135 |
| Grifols USA, LLC | 7 | $113 |
| Bayer | 5 | $97 |
| Actelion Pharmaceuticals US, Inc. | 6 | $88 |
| Sanofi | 6 | $82 |
| Inspire Medical Systems, Inc. | 3 | $73 |
| Stryker | 2 | $67 |
| AbbVie | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 5 | $61 |
| Regeneron Healthcare Solutions, Inc. | 4 | $60 |
| Mylan Specialty L.p. | 4 | $56 |
| Genentech USA, Inc. | 4 | $54 |
| Electronic Waveform Lab, Inc. | 1 | $49 |
| Novartis | 3 | $40 |
| La Jolla Pharmaceutical Company | 2 | $39 |
| Dynasplint Systems Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Vapotherm Inc | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Electromed, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Merck | 1 | $14 |
| Amgen | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Insmed, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,723 in reported general payments places this provider in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 261 | $223,406 |
| OpsumitMacitentan | 12 | $148,047 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $77,515 |
| Spiriva HandihalerTiotropium Bromide | 41 | $29,330 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $28,710 |
| Incruse ElliptaUmeclidinium Bromide | 53 | $21,819 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 99 | $15,555 |
| Spiriva RespimatTiotropium Bromide | 28 | $15,534 |
| Advair HfaFluticasone Propion/Salmeterol | 38 | $14,523 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $14,010 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $12,245 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $11,253 |
| Tiotropium Bromide | 18 | $7,742 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 202 | $6,750 |
| Wixela InhubFluticasone Propion/Salmeterol | 44 | $4,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $377 | $334,985458 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $88 | $148,04712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $583 | $39,96272 claims |
| Boehringer IngelheimSpiriva Respimat | $9,729 | $15,53428 claims |
| MerckDulera | $14 | $2,73111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Freehold
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.